{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:41:06Z","timestamp":1707525666682},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,23]]},"DOI":"10.7759\/cureus.52828","type":"journal-article","created":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T05:05:54Z","timestamp":1706072754000},"source":"Crossref","is-referenced-by-count":0,"title":["Biosimilar in Breast Cancer: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Diplina","family":"Barman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tibar","family":"Bandyopadhyay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rounik","family":"Talukdar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2018.01.006","article-title":"The global need for a trastuzumab biosimilar for patients with HER2-positive breast cancer","volume":"18","author":"Blackwell K","year":"2018","unstructured":"Blackwell K, Gligorov J, Jacobs I, Twelves C. The global need for a trastuzumab biosimilar for patients with HER2-positive breast cancer. Clin Breast Cancer. 2018, 18:95-113. 10.1016\/j.clbc.2018.01.006","journal-title":"Clin Breast Cancer"},{"key":"ref2","unstructured":"Breast cancer. (2023). Accessed. November 24, 2023: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/breast-cancer."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2018-0957","article-title":"Current situation and challenges regarding biosimilars in Japan: an example of trastuzumab biosimilars for breast cancer","volume":"15","author":"Hara F","year":"2019","unstructured":"Hara F, Tajima K, Tanabe K. Current situation and challenges regarding biosimilars in Japan: an example of trastuzumab biosimilars for breast cancer. Future Oncol. 2019, 15:1353-61. 10.2217\/fon-2018-0957","journal-title":"Future Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013539","article-title":"Biosimilar monoclonal antibodies for cancer treatment","volume":"2020","author":"Galv\u00e3o TF","year":"2020","unstructured":"Galv\u00e3o TF, Livinalli A, Lopes LC, Zimmermann IR, Silva MT. Biosimilar monoclonal antibodies for cancer treatment. Cochrane Database Syst Rev. 2020, 2020:CD013539. 10.1002\/14651858.CD013539","journal-title":"Cochrane Database Syst Rev"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/GO.20.00649","article-title":"Biosimilar use in breast cancer treatment: a national survey of Brazilian oncologists\u2019 opinions, practices, and concerns","volume":"7","author":"Resende HM","year":"2021","unstructured":"Resende HM, Ladislau L, Cardoso AC, et al.. Biosimilar use in breast cancer treatment: a national survey of Brazilian oncologists\u2019 opinions, practices, and concerns. JCO Glob Oncol. 2021, 7:1316-24. 10.1200\/GO.20.00649","journal-title":"JCO Glob Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0480-z","article-title":"The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars","volume":"121","author":"Barbier L","year":"2019","unstructured":"Barbier L, Declerck P, Simoens S, Neven P, Vulto AG, Huys I. The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars. Br J Cancer. 2019, 121:199-210. 10.1038\/s41416-019-0480-z","journal-title":"Br J Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14050927","article-title":"Monoclonal antibody functionalized, and L-lysine \u03b1-oxidase loaded pegylated-chitosan nanoparticle for HER2\/neu targeted breast cancer therapy","volume":"14","author":"Saravanakumar K","year":"2022","unstructured":"Saravanakumar K, Sathiyaseelan A, Park S, Kim SR, Priya VV, Wang MH. Monoclonal antibody functionalized, and L-lysine \u03b1-oxidase loaded pegylated-chitosan nanoparticle for HER2\/neu targeted breast cancer therapy. Pharmaceutics. 2022, 14:927. 10.3390\/pharmaceutics14050927","journal-title":"Pharmaceutics"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2019.1638362","article-title":"Biosimilars for breast cancer","volume":"19","author":"Migliavacca Zucchetti B","year":"2019","unstructured":"Migliavacca Zucchetti B, Nicol\u00f2 E, Curigliano G. Biosimilars for breast cancer. Expert Opin Biol Ther. 2019, 19:1015-21. 10.1080\/14712598.2019.1638362","journal-title":"Expert Opin Biol Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2018.03.018","article-title":"Monoclonal antibody biosimilars in oncology: critical appraisal of available data on switching","volume":"40","author":"Declerck P","year":"2018","unstructured":"Declerck P, Bakalos G, Zintzaras E, Barton B, Schreitm\u00fcller T. Monoclonal antibody biosimilars in oncology: critical appraisal of available data on switching. Clin Ther. 2018, 40:798-809.e2. 10.1016\/j.clinthera.2018.03.018","journal-title":"Clin Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2022.01.007","article-title":"Efficacy of CT-P6 (trastuzumab biosimilar) versus reference trastuzumab in combination with pertuzumab in HER2-positive early-stage breast cancer: preclinical and real-life clinical data","volume":"62","author":"Bernat-Peguera A","year":"2022","unstructured":"Bernat-Peguera A, Trigueros M, Ferrando-D\u00edez A, et al.. Efficacy of CT-P6 (trastuzumab biosimilar) versus reference trastuzumab in combination with pertuzumab in HER2-positive early-stage breast cancer: preclinical and real-life clinical data. Breast. 2022, 62:1-9. 10.1016\/j.breast.2022.01.007","journal-title":"Breast"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics10040168","article-title":"Concepts and challenges of biosimilars in breast cancer: the emergence of trastuzumab biosimilars","volume":"10","author":"Uif\u0103lean A","year":"2018","unstructured":"Uif\u0103lean A, Ilie\u015f M, Nicoar\u0103 R, Rus LM, Heghe\u015f SC, Iuga CA. Concepts and challenges of biosimilars in breast cancer: the emergence of trastuzumab biosimilars. Pharmaceutics. 2018, 10:168. 10.3390\/pharmaceutics10040168","journal-title":"Pharmaceutics"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01601-2","article-title":"Safety, immunogenicity and interchangeability of biosimilar monoclonal antibodies and fusion proteins: a regulatory perspective","volume":"81","author":"Kurki P","year":"2021","unstructured":"Kurki P, Barry S, Bourges I, Tsantili P, Wolff-Holz E. Safety, immunogenicity and interchangeability of biosimilar monoclonal antibodies and fusion proteins: a regulatory perspective. Drugs. 2021, 81:1881-96. 10.1007\/s40265-021-01601-2","journal-title":"Drugs"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/bit.26438","article-title":"Biosimilars: key regulatory considerations and similarity assessment tools","volume":"114","author":"Kirchhoff CF","year":"2017","unstructured":"Kirchhoff CF, Wang XM, Conlon HD, Anderson S, Ryan AM, Bose A. Biosimilars: key regulatory considerations and similarity assessment tools. Biotechnol Bioeng. 2017, 114:2696-705. 10.1002\/bit.26438","journal-title":"Biotechnol Bioeng"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01411-y","article-title":"Targeting HER2 in breast cancer: latest developments on treatment sequencing and the introduction of biosimilars","volume":"80","author":"Tesch ME","year":"2020","unstructured":"Tesch ME, Gelmon KA. Targeting HER2 in breast cancer: latest developments on treatment sequencing and the introduction of biosimilars. Drugs. 2020, 80:1811-30. 10.1007\/s40265-020-01411-y","journal-title":"Drugs"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108433","article-title":"A comprehensive review on immuno-nanomedicine for breast cancer therapy: technical challenges and troubleshooting measures","volume":"103","author":"Saravanakumar K","year":"2022","unstructured":"Saravanakumar K, Anbazhagan S, Pujani Usliyanage J, et al.. A comprehensive review on immuno-nanomedicine for breast cancer therapy: technical challenges and troubleshooting measures. Int Immunopharmacol. 2022, 103:108433. 10.1016\/j.intimp.2021.108433","journal-title":"Int Immunopharmacol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2021.1849132","article-title":"A health economic guide to market access of biosimilars","volume":"21","author":"Simoens S","year":"2021","unstructured":"Simoens S, Vulto AG. A health economic guide to market access of biosimilars. Expert Opin Biol Ther. 2021, 21:9-17. 10.1080\/14712598.2021.1849132","journal-title":"Expert Opin Biol Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/221543-biosimilar-in-breast-cancer-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:12:20Z","timestamp":1707509540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/221543-biosimilar-in-breast-cancer-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,23]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.52828","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,23]]}}}